UNICA IRIS Institutional Research Information System

MULAS, OLGA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 42.096
NA - Nord America 1.671
AS - Asia 246
SA - Sud America 11
AF - Africa 3
Totale 44.027
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 41.654
US - Stati Uniti d'America 1.662
SE - Svezia 184
CN - Cina 118
DE - Germania 70
FI - Finlandia 60
UA - Ucraina 58
KR - Corea 33
SG - Singapore 30
GB - Regno Unito 29
IN - India 17
VN - Vietnam 16
HK - Hong Kong 11
PL - Polonia 10
CA - Canada 9
BR - Brasile 8
FR - Francia 8
IR - Iran 5
JO - Giordania 5
AT - Austria 4
IE - Irlanda 4
ID - Indonesia 3
JP - Giappone 3
NL - Olanda 3
RU - Federazione Russa 3
BE - Belgio 2
EG - Egitto 2
ES - Italia 2
IQ - Iraq 2
AR - Argentina 1
BF - Burkina Faso 1
BG - Bulgaria 1
BO - Bolivia 1
CH - Svizzera 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
MY - Malesia 1
NO - Norvegia 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 44.027
Salva come PNG Salva come JPEG
Città #
Cagliari 41.320
Fairfield 231
Ashburn 160
Nyköping 145
Woodbridge 134
Chandler 123
Seattle 115
Houston 110
Cambridge 102
New York 93
Wilmington 93
Ann Arbor 64
Helsinki 56
Boardman 54
Shanghai 42
Rome 41
Incheon 33
Beijing 31
Boston 27
Milan 23
Dearborn 21
San Diego 20
Jacksonville 19
Dong Ket 16
Redwood City 15
Krefeld 11
Nanjing 11
Bologna 10
London 10
Atlanta 9
Hong Kong 8
Mountain View 8
Rio de Janeiro 8
Alghero 7
Pune 7
Redmond 7
Warsaw 7
Los Angeles 6
Toronto 6
Turin 6
Amman 5
Borghetto di Borbera 5
Changsha 5
Elmas 5
Gonnesa 5
Nanchang 5
Naples 5
Bad Bellingen 4
Biella 4
Dublin 4
Fuzhou 4
Miano 4
Norwalk 4
Ragusa 4
San Mateo 4
Umeå 4
Washington 4
Brescia 3
Certaldo 3
Council Bluffs 3
Detroit 3
Genoa 3
Hefei 3
Macomer 3
Manta 3
Messina 3
Nuoro 3
Quartu Sant'Elena 3
Sorso 3
Tianjin 3
Trentola-Ducenta 3
Venezia 3
Vienna 3
Zhengzhou 3
Acton 2
Amsterdam 2
Andover 2
Arbus 2
Bari 2
Borås 2
Brussels 2
Carbonia 2
Casavatore 2
Collegno 2
Corigliano Calabro 2
Deiva Marina 2
Dello 2
Dokki 2
Faridabad 2
Follo 2
Frankfurt am Main 2
Giarre 2
Glasgow 2
Jinan 2
Kolkata 2
Kuningan Barat 2
Kunming 2
Kuy-e Ekhtesasi-ye Gomrok 2
Livorno 2
Loceri 2
Totale 43.387
Salva come PNG Salva come JPEG
Nome #
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.129
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 2.906
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.826
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 2.721
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.410
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.211
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 1.900
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 1.823
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.674
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.668
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.596
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 1.562
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.557
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.379
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 1.279
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.244
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.226
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.153
Ruolo del trapianto allogenico nelle talassemie 795
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 674
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors 571
Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis 543
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis 533
Risk and Response-Adapted Treatment in Multiple Myeloma 514
Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials 411
Conditioning Regimens in Patients with β-Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review 402
Health-Related Quality-of-Life Profile of Pediatric Patients with β Thalassemia after Hematopoietic Stem Cell Transplantation 374
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 363
Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy 350
Long-term health-related quality of life in patients with beta-thalassemia after unrelated hematopoietic stem cell transplantation 326
Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine 290
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome 286
Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report 264
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network 252
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study 251
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib? 231
Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation 224
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia 222
Systematic Review and Meta-Analysis of Health-Related Quality of Life in Patients with β-Thalassemia Underwent Hematopoietic Stem Cell Transplantation 222
Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation 213
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 182
Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with β-Thalassemia after Splenectomy 162
Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules 146
Low adherence to therapy and co-morbid depressive episodes are independent determinants of early death in people with cancer 140
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension 136
Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform 108
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura 106
The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia 102
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 95
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help 73
Adherence to treatment in patients with solid and hematological cancers. Could spiritual and psychological support facilitate optimal adherence? 56
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 48
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia 46
Association of Hypometilating Agents (HMA) plus Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine 38
Increase of Arterial Stiffness in Patients with Polycythemia Vera 37
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 34
Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study 33
Infectious Complications in Autoimmune Hemolytic Anemia: A Multi-Center Italian Experience 32
Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase 30
On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML) 28
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study 28
Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura 16
Totale 44.251
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019146 0 0 0 0 0 0 0 0 0 0 66 80
2019/20205.894 177 120 43 120 1.960 1.629 894 212 153 155 149 282
2020/202113.973 345 643 592 3.787 2.426 1.582 945 886 376 1.043 848 500
2021/20225.564 448 372 235 320 437 382 265 281 533 736 903 652
2022/20237.277 430 861 931 581 539 826 413 599 506 521 712 358
2023/20247.412 389 300 383 540 675 1.558 1.186 666 556 612 547 0
Totale 44.251